Latest Breaking News On - Y alan wang - Page 1 : comparemela.com

MD Anderson Research Highlights for May 18, 2022

MD Anderson research highlights for September 22, 2021

Proactive Investors China - The web's leading portal for China stocks - Charlie Teo Foundation grant to fund key research of new Pharmaxis drug to tackle brain cancer

2021-05-03 by Proactive Australia Pharmaxis Ltd (ASX:PXS)(FRA:UUD) drug discovery PXS-5505 will be the focus of a new study funded by a grant from the Charlie Teo Foundation, an Australian charity, for key research into a drug discovery tackling an aggressive and deadly form of brain cancer. The drug, PXS-5505, which has commenced a phase 1/2a clinical trial for the rare bone marrow cancer myelofibrosis, will now enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis. A$186,837 research grant Charlie Teo Foundation has awarded a A$186,837 research grant to Y Alan Wang, PhD, associate professor of Cancer Biology at The University of Texas MD Anderson Cancer Center to enable the study of PXS-5505.

Charlie Teo Foundation grant to fund key research of new Pharmaxis Ltd drug to tackle brain cancer

Charlie Teo Foundation grant to fund key research of new Pharmaxis drug to tackle brain cancer PXS-5505 will enter pre-clinical efficacy testing for glioblastoma, the most common form of brain cancer with an average survival of only 15 months from diagnosis. Charlie Teo Foundation founder and director Professor Charlie Teo and Pharmaxis CEO Gary Phillips during a TV interview. Pharmaxis Ltd (ASX:PXS) (FRA:UUD) drug discovery PXS-5505 will be the focus of a new study funded by a grant from the Charlie Teo Foundation, an Australian charity, for key research into a drug discovery tackling an aggressive and deadly form of brain cancer.

Charlie Teo Foundation grant to fund key research of new Pharmaxis Ltd drug to tackle brain cancer